Eczema Play Heals Its Chart With a 20% Pop

A biotech firm is erupting after its eczema drug crushed expectations in mid-stage trials. A tech heavyweight is winning in Hollywood but losing investor patience with AI. And a little-known herbal medicine stock is on a retail-fueled tear for the second time in a week. Here’s what traders are watching.

Every strong portfolio starts with a reliable core — and this new report may help investors build exactly that.

“7 Stocks to Buy and Hold Forever” highlights a group of companies with a track record of steady performance, strong fundamentals, and long-term growth potential.

For a limited time, this full report is being offered at no cost.

These stocks were chosen for a reason — and could help lay the groundwork for a strategy built to outlast short-term swings.

[Access the report free here]

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our premarket report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings:

Economic Reports:

While headlines focus on the same overhyped AI names, a bigger opportunity is taking shape — and it’s flying under the radar.

A new report reveals 9 AI companies with real U.S. operations, accelerating revenue, and deep AI integration. These aren’t speculative plays — they’re positioned to benefit from a massive shift in how and where AI is being built.

This free guide includes:

…plus 6 more names with major upside potential.

The early window on these opportunities may be closing — now’s the time to see what’s coming next.

[Get your FREE copy now]

Apple (AAPL) is down 0.5% in premarket trading on Monday, as investors digest mixed signals about the tech giant’s direction. While the company scored a major success with its first blockbuster film, “F1,” Wall Street remains unconvinced by Apple’s recent AI strategy.

“F1” earned over $155 million in its opening weekend and showcased the strength of Apple’s services arm — a growing profit center that includes Apple TV+, Music, and iCloud.

The film’s success marks a milestone in Apple’s push to become a major Hollywood player, years after the company launched Apple TV+ to skepticism.

But the celebration has been tempered by investor unease about Apple’s lagging AI rollout. At last month’s WWDC, the company revealed a few updates on “Apple Intelligence” and delayed key improvements to Siri until 2026.

Reports that Apple may turn to outside partners, such as OpenAI or Anthropic, instead of using its own models have raised eyebrows, given the company’s long-standing preference for building core technology in-house.

As rivals like Meta and Google rapidly expand their AI capabilities and talent pools, Apple’s slow progress is raising red flags.

The contrast between its box office success and strategic stumbles in AI is fueling concerns about whether Apple can remain competitive at the cutting edge of consumer tech over the next decade.

Regencell Bioscience (RGC) climbed another 6% in premarket trading Monday, extending last week’s massive 121.9% surge that stunned investors. The Hong Kong–based biotech firm, which focuses on traditional Chinese herbal therapies for ADHD and autism, has now gained more than 17,000% year-to-date, making it one of 2025’s most extreme performers.

Despite the rally, the company has no FDA-approved drugs, no active revenue streams, and remains in the early stages of clinical development. Its treatments lack peer-reviewed data or intellectual property protections, and Regencell has posted six consecutive years of net losses, most recently incurring a loss of $1.85 million in the second half of 2024.

Still, RGC continues to attract heavy interest from retail traders following a 38-for-1 stock split in June, which significantly lowered the share price and increased accessibility. The company has also claimed a recent surge may have been fueled by a short squeeze, though market data shows limited short interest.

With few shares outstanding and tightly held insider ownership, the stock’s low float and speculative appeal have created the perfect storm for extreme volatility.

While some investors see potential in Regencell’s unconventional approach to neurological disorders, the company’s valuation remains detached from its fundamentals, drawing comparisons to past phenomena of meme stocks.

Starting this July, big banks can legally treat gold as cash—and they’re wasting no time.

Meanwhile, millions of Americans are still heavily invested in volatile paper assets.

One economist says gold is now “the only money banks trust.”

There’s still time to catch up, using an IRS-approved method that avoids taxes or penalties.

This FREE Wealth Protection Guide explains how to move before the window closes.

[Click here to access the guide]

P.S. Every day you wait, the insiders move further ahead. Get the facts before July hits.

Apogee Therapeutics (APGE) shares are up nearly 20% in premarket trading after the company reported blockbuster results from its Phase 2 APEX Part A trial for APG777, a novel anti-IL-13 biologic targeting moderate-to-severe atopic dermatitis.

The treatment met all primary and key secondary endpoints, including a 71.0% reduction in Eczema Area and Severity Index (EASI) scores and a 66.9% EASI-75 response rate, the highest ever seen for a biologic in a global study for the condition.

The trial enrolled 123 patients and employed a low-frequency dosing regimen, comprising just four injections over 16 weeks, delivering rapid itch relief by Week 1 and a robust safety profile.

Patients in the top two exposure groups experienced particularly impressive results, with EASI-75 rates as high as 89.5%, and no injection site reactions were reported. Based on these findings, Apogee has accelerated Part B of the trial to test higher doses, with readouts now expected by mid-2026.

The company also plans to initiate Phase 3 studies next year and is progressing with a head-to-head trial of its dual-inhibitor APG279 versus the blockbuster drug Dupixent. That trial could yield additional data in the second half of 2026.

CEO Michael Henderson called the data “transformational” and emphasized the potential to establish quarterly or better dosing as a new standard of care. With atopic dermatitis representing a multi-billion-dollar market and current biologics requiring more frequent injections, APG777’s long half-life and efficacy profile may offer a meaningful competitive edge.

The news significantly de-risks Apogee’s lead program and validates its broader strategy to engineer extended half-life antibodies across multiple inflammatory and immunology indications.

Investors appear to agree as the stock is on track for one of its biggest single-day gains since going public.

Clover Health is a technology-driven Medicare Advantage insurer focused on lowering healthcare costs using its data platform, Clover Assistant. The company has undergone multiple strategic overhauls to boost margins and drive growth.

The stock is up nearly 3.2% in premarket trading, continuing a broader 148% 1-year run. Traders appear to be piling in following recent chatter about potential consolidation in the Medicare Advantage space and an uptick in risk-on sentiment among retail investors.

Shoals Technologies designs and manufactures electrical balance-of-systems solutions for solar energy projects. The company provides essential components, including cabling, connectors, and monitoring hardware.

Shares are up 4% in premarket trading after a wave of bullish activity hit the solar sector. Analysts are warming up to SHLS again, citing valuation disconnects and renewed momentum in U.S. renewable infrastructure spending.

Bit Digital is a bitcoin mining company with operations in North America, tapping into clean energy sources and scaling AI-focused infrastructure. It has become a favorite among crypto-aligned retail traders.

The stock is up nearly 9% in premarket trading, following a broader bounce in bitcoin-related equities tied to new capital inflows and improved sentiment after last week’s macroeconomic signals.

As we dive into Q2 2025, the stock market is buzzing with opportunities, and I’ve got the insider scoop just for you.

I’ve handpicked the Top Seven Stocks for this quarter, offering you a clear roadmap for growth as the year progresses.

Here’s what makes this guide indispensable:

This isn’t merely a list; it’s your chance to seize the market’s hottest opportunities before they pass you by.

[Get Your Free Guide Now]

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.